- Eli Lilly announced FDA approval of Onswik, a once-weekly basal insulin for adults with type 2 diabetes, indicated for use with diet and exercise to control high blood sugar.
- Onswik's weekly dosing contrasts with standard once-daily basal insulins, reducing injection frequency for patients managing type 2 diabetes.
- The approval adds a differentiated diabetes product to Lilly's portfolio, where the company is already a major player in the GLP-1 and incretin market.
Quotes
“Eli Lilly (LLY) on Thursday announced that the U.S. FDA approved its once-weekly basal insulin product, Onswik, for adults with type 2 diabetes to be used with diet and exercise for the control of high blood sugar.”